IL17RA gene variants and anti-TNF response among psoriasis patients

Polymorphisms at genes encoding proteins involved in the pathogenesis of psoriasis (Psor) or in the mechanism of action of biological drugs could influence the treatment response. Because the interleukin (IL)-17 family has a central role in the pathogenesis of Psor, we hypothesized that IL17RA varia...

Full description

Saved in:

Bibliographic Details
Published in:	The pharmacogenomics journal Vol. 18; no. 1; pp. 76 - 80
Main Authors:	Batalla, A, Coto, E, Gómez, J, Eirís, N, González-Fernández, D, Gómez-De Castro, C, Daudén, E, Llamas-Velasco, M, Prieto-Perez, R, Abad-Santos, F, Carretero, G, García, F S, Godoy, Y B, Cardo, L F, Alonso, B, Iglesias, S, Coto-Segura, P
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-01-2018 Nature Publishing Group
Subjects:	631/208/1516 692/308/2056 Adalimumab - therapeutic use Alleles Biomedical and Life Sciences Biomedicine Care and treatment Cross-Sectional Studies Drug therapy Etanercept Etanercept - therapeutic use Female Gene Expression Genetic aspects Genotype Human Genetics Humans Infliximab Infliximab - therapeutic use Interleukin 1 Interleukin-17 - genetics Interleukins Male Middle Aged Monoclonal antibodies Oncology original-article Pathogenesis Pharmacotherapy Physiological aspects Polymorphism Polymorphism, Single Nucleotide - genetics Population studies Proteins Psoriasis Psoriasis - drug therapy Psoriasis - genetics Psychopharmacology Receptors, Interleukin-17 - genetics Single nucleotide polymorphisms Single-nucleotide polymorphism Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-α Spain
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Polymorphisms at genes encoding proteins involved in the pathogenesis of psoriasis (Psor) or in the mechanism of action of biological drugs could influence the treatment response. Because the interleukin (IL)-17 family has a central role in the pathogenesis of Psor, we hypothesized that IL17RA variants could influence the response to anti-TNF drugs among Psor patients. To address this issue we performed a cross-sectional study of Psor patients who received the biological treatments for the first time, with a follow-up of at least 6 months. All of the patients were Caucasian, older than 18 years old, with chronic plaque Psor, and had completed at least 24 weeks of anti-TNF therapy (adalimumab, etanercept or infliximab). The treatment response to anti-TNF agents was evaluated according to the achievement of PASI50 and PASI75 at weeks 12 and 24. Those who achieved PASI75 at week 24 were considered good responders. All patients were genotyped for the selected single-nucleotide polymorphisms (SNPs) at IL17RA gene. A total of 238 patients were included (57% male, mean age 46 years). One hundred and five patients received adalimumab, 91 patients etanercept and 42 infliximab. The rs4819554 promoter SNP allele A was significantly more common among responders at weeks 12 ( P =0.01) and 24 ( P =0.04). We found a higher frequency of AA versus AG+GG among responders, but the difference was only significant at week 12 ( P =0.03, odd ratio=1.86, 95% confidence of interval=1.05–3.27). Thus, in the study population, the SNP rs4819554 in the promoter region of IL17RA significantly influences the response to anti-TNF drugs at week 12.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1470-269X 1473-1150
DOI:	10.1038/tpj.2016.70